What IQVIA Holders Bought Into
For IQVIA shareholders, the return over the past year was 25.8%, including dividends. If you had been weighing a buy on 26 October 2025, you would have seen bullish analysts leaning on NVIDIA powered AI deployment and a US$268 fair value, while skeptics pointed to heavy debt, tighter data rules, and only modest margin improvement. With that split on record, which side of the IQVIA debate would have looked more convincing to you at the time?
The move put IQVIA in the middle of this trade. Scan 34 healthcare AI stocks for other companies exposed to it.
The Two Futures Investors Were Arguing About With IQVIA
The shares cost US$221 at the start of the period, so any view on IQVIA had to start with whether that entry point matched your conviction on its AI and data ambitions.
The bullish narrative pointed to a Fair Value of US$268, a price level implied by its scenario, built on faster growth from real world data analytics and NVIDIA backed generative AI tools that could reshape efficiency and client adoption.
The bearish side anchored on a Fair Value of US$168, based on tighter data privacy rules and a heavy debt load that could restrict flexibility and potentially pressure future earnings power.
What The Results Changed In The IQVIA Debate
IQVIA used the period to expand AI enabled offerings, such as the Kexing Biopharm collaboration and the IQVIA.ai rollout, which backed the optimistic case around data and automation. The Q2 2026 report told a different story. Revenue reached US$4,368m versus US$4,017m a year earlier, but net income slipped and net margin fell from 6.6% to 5.9%, so profitability progress looked more cautious.
The clear swing factor was not just AI headlines but whether higher sales converted into richer margins. For any similar stock, track net margin alongside top line and compare it to the thesis that was built on future efficiency gains.
What IQVIA's Higher Fair Value Narrative Asks You To Believe Now
IQVIA shares now trade at US$274, with this selected Narrative arguing that its Fair Value sits above the current price rather than below it.
The case leans on AI enabled clinical and commercial tools turning a large backlog and pipeline into sustained organic growth and steadier margins. The question is whether robust conversion of that R&DS and Commercial Solutions work really persists from here.
"Key Takeaways: Bullish analysts expect IQVIA Holdings to keep gaining from AI enabled real world data and clinical tools, with recent AI agent deployment and contract wins reinforcing that this engine is still early in its commercial impact. The main requirement is that IQVIA converts its growing R&DS backlog, emerging biopharma mix, and Commercial Solutions pipeline into sustained organic growth, while using AI to support margins despite client insourcing concerns."
Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there
Which Company Could Surprise You Next?
The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?
- Company 1 - 30% below our estimate - positions critical chips and software where digital workloads must be processed, moved and secured.
- Company 2 - 39% below our estimate - scales device trade in and refurbishment as consumers and policies push harder toward recycling.
- Company 3 - 27% below our estimate - builds liquid cooling and power systems needed for high density AI data centre racks.
Three companies from the same screener. Open every one of the 29 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com